Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
52.02 USD | -0.42% | +0.23% | -6.27% |
05-31 | Piper Sandler Starts Arcellx With Overweight Rating, $70 Price Target | MT |
05-15 | Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.27% | 2.78B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.32% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- ACLX Stock
- News Arcellx, Inc.
- Arcellx Says US FDA Placed Clinical Hold on Multiple Myeloma Therapy Phase 2 Trial Following Patient Death